F. Bumol, Ph.D.
Dr. Bumol has served on our board of directors since February 2019. Dr. Bumol is executive director of the Allen Institute for Immunology in Seattle, Washington. He joined the Allen Institute for Immunology in 2018 following a 35-year career at Eli Lilly and Company, where he was most recently the senior vice-president of biotechnology and immunology research and the site head of Lilly’s Biotechnology Center in San Diego, California. While at Lilly, Dr. Bumol’s teams and collaborators advanced over 100 molecules into clinical development, including TRULICITY® (dulaglutide), TALTZ®(ixekizumab), EMGALITY® (galcanezumab) and mirikizumab. Through strategic alliances, he and his teams also helped develop and support REOPRO® (abciximab) with Centocor as well as OLUMIANT® (baricitinib) with Incyte. Dr. Bumol earned his B.S. degree in microbiology from the University of Michigan and his Ph.D. in microbiology-immunology from the University of Minnesota. He completed postdoctoral studies through a fellowship in the department of molecular immunology at Scripps Research in La Jolla, California.